Procainamide Antibody (704): sc-57985

Procainamide Antibody (704) is a mouse monoclonal IgG1 antibody that detects Procainamide protein of non-species reactive by enzyme-linked immunosorbent assay (ELISA). Anti-Procainamide antibody (704) is available as a non-conjugated format, specifically designed for research applications. Procainamide, a class Ia antiarrhythmic drug, plays a crucial role in managing cardiac arrhythmias by blocking open sodium channels, which prolongs cardiac action potential. This mechanism slows conduction velocity and decreases the rate of action potential rise, potentially resulting in a widened QRS complex on an electrocardiogram. The active metabolite, N-acetyl procainamide, is excreted by the kidneys, highlighting the importance of renal function in drug efficacy and safety. While Procainamide effectively treats both supraventricular and ventricular arrhythmias, monitoring for side effects such as rash, myalgia, and hypersensitivity reactions remains essential, along with potential antibody production against cellular components leading to systemic lupus erythematosus-like reactions. Procainamide monoclonal antibody (704) serves as a valuable tool for researchers studying the pharmacodynamics and safety of this therapeutic agent.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Procainamide Antibody (704) References:

1. Transport of procainamide in a kidney epithelial cell line LLC-PK1.  |  Takano, M., et al. 1992. Biochim Biophys Acta. 1108: 133-9. PMID: 1637838
2. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.  |  Kim, SY. and Benowitz, NL. 1990. Drug Saf. 5: 393-420. PMID: 2285495
3. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.  |  Funck-Brentano, C., et al. 1989. J Cardiovasc Pharmacol. 14: 364-73. PMID: 2476614
4. Predicting ventricular tachycardia cycle length after procainamide by assessing cycle length-dependent changes in paced QRS duration.  |  Marchlinski, FE., et al. 1989. Circulation. 79: 39-46. PMID: 2910546
5. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias.  |  Giardina, EG. 1984. Ann N Y Acad Sci. 432: 177-88. PMID: 6084435
6. N-acetyl procainamide causing torsades de pointes.  |  Olshansky, B., et al. 1982. Am J Cardiol. 50: 1439-41. PMID: 6183970
7. Procainamide: a perspective on its value and danger.  |  Ellenbogen, KA., et al. 1993. Heart Dis Stroke. 2: 473-6. PMID: 8137053
8. Dual actions of procainamide on batrachotoxin-activated sodium channels: open channel block and prevention of inactivation.  |  Zamponi, GW., et al. 1993. Biophys J. 65: 2324-34. PMID: 8312472
9. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.  |  Dutcher, JS., et al. 1977. Clin Pharmacol Ther. 22: 447-57. PMID: 902457